All Publications

Export 160 results:
Author Title Type [ Year(Asc)]
2012
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth J, van Sighem A, Kirk O, Obel N, Panos G et al. Int J Epidemiol, 2012 Apr, Volume 41, Issue 2, p.433-45, (2012)
CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, Gutiérrez F et al. PLoS Med, 2012, Volume 9, Issue 3, p.e1001194, (2012)
Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study. Price H, Bansi L, Sabin C, Bhagani S, Burroughs A, Chadwick D, Dunn D, Fisher M, Main J, Nelson M et al. PLoS One, 2012, Volume 7, Issue 11, p.e49314, (2012)
2011
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A, Gilson R, Gazzard B et al. BMJ, 2011 Oct 11, Volume 343, p.d6016, (2011)
Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study. Hughes R, Sterne J, Walsh J, Bansi L, Gilson R, Orkin C, Hill T, Ainsworth J, Anderson J, Gompels M et al. HIV Med, 2011 Nov, Volume 12, Issue 10, p.583-93, (2011)
Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters. Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C, Bansi L, Gompels M et al. HIV Med, 2011 May, Volume 12, Issue 5, p.289-98, (2011)
The impact of HIV drug resistance testing on changes to treatment. Bansi L, Smith C, Phillips A, Kirk S, Geretti A, Johnson M, Mackie N, Post F, Gazzard B, Dunn D et al. AIDS, 2011 Mar 13, Volume 25, Issue 5, p.603-10, (2011)
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T et al. Eur J Neurol, 2011 Mar, Volume 18, Issue 3, p.527-34, (2011)
Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T et al. Neurology, 2011 Feb 22, Volume 76, Issue 8, p.693-700, (2011)
Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception. Huntington S, Bansi L, Thorne C, Anderson J, Newell M, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. AIDS, 2011 Aug 24, Volume 25, Issue 13, p.1647-55, (2011)
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Cain L, Logan R, Robins J, Sterne J, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F et al. Ann Intern Med, 2011 Apr 19, Volume 154, Issue 8, p.509-15, (2011)
Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score. Cozzi-Lepri A, Prosperi M, Kjær J, Dunn D, Paredes R, Sabin C, Lundgren J, Phillips A and Pillay D. PLoS One, 2011, Volume 6, Issue 11, p.e25665, (2011)
Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Barber T, Geretti A, Anderson J, Schwenk A, Phillips A, Bansi L, Gilson R, Hill T, Walsh J, Fisher M et al. Antivir Ther, 2011, Volume 16, Issue 6, p.805-14, (2011)
2010
Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK. Fox J, Castro H, Kaye S, McClure M, Weber J and Fidler S. AIDS, 2010 Sep 24, Volume 24, Issue 15, p.2397-401, (2010)
Data linkage reduces loss to follow-up in an observational HIV cohort study. Hill T, Bansi L, Sabin C, Phillips A, Dunn D, Anderson J, Easterbrook P, Fisher M, Gazzard B, Gilson R et al. J Clin Epidemiol, 2010 Oct, Volume 63, Issue 10, p.1101-9, (2010)
Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. Mackie N, Phillips A, Kaye S, Booth C and Geretti A. J Infect Dis, 2010 May 01, Volume 201, Issue 9, p.1303-7, (2010)
Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. . Clin Infect Dis, 2010 May 01, Volume 50, Issue 9, p.1275-85, (2010)
Late diagnosis in the HAART era: proposed common definitions and associations with mortality. Sabin C, Schwenk A, Johnson M, Gazzard B, Fisher M, Walsh J, Orkin C, Hill T, Gilson R, Porter K et al. AIDS, 2010 Mar 13, Volume 24, Issue 5, p.723-7, (2010)
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Lodwick R, Costagliola D, Reiss P, Torti C, Teira R, Dorrucci M, Ledergerber B, Mocroft A, Podzamczer D, Cozzi-Lepri A et al. Arch Intern Med, 2010 Mar 08, Volume 170, Issue 5, p.410-9, (2010)
The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. Harrison L, Castro H, Cane P, Pillay D, Booth C, Phillips A, Geretti A and Dunn D. AIDS, 2010 Jul 31, Volume 24, Issue 12, p.1917-22, (2010)
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lodwick R, Sabin C, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobson L, De Wit S et al. Lancet, 2010 Jul 31, Volume 376, Issue 9738, p.340-5, (2010)
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. Ray M, Logan R, Sterne J, Hernández-Díaz S, Robins J, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D et al. AIDS, 2010 Jan 02, Volume 24, Issue 1, p.123-37, (2010)
Factors influencing lopinavir and atazanavir plasma concentration. Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Gazzard B et al. J Antimicrob Chemother, 2010 Jan, Volume 65, Issue 1, p.129-37, (2010)
Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. Gilson R, Man S, Copas A, Rider A, Forsyth S, Hill T, Bansi L, Porter K, Gazzard B, Orkin C et al. HIV Med, 2010 Feb, Volume 11, Issue 2, p.152-60, (2010)
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, Chadborn T, Easterbrook P, Gilson R, Johnson M et al. HIV Med, 2010 Aug, Volume 11, Issue 7, p.432-8, (2010)